Effect of nesiritide on renal function in patients admitted for decompensated heart failure

QJM: An International Journal of Medicine

Volumn 100, Issue 11, 2007, Pages 699-706

  Arora, S ^a   Clarke, K ^b   Srinivasan, V ^a   Gradman, A ^a  

^a TEMPLE UNIVERSITY   (United States)

^b WESTERN PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NESIRITIDE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DETERIORATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 35748979704     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm089     Document Type: Article

References (20)

1. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681-9.
2. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen levels as predictor of mortality in patients admitted for decompensated heart failure. Am J Med 2004; 116:466-73.
3. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109:1004-9.
4. Krumholz HM; Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RI. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol 2000; 85:1110-13.
5. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal functions among hospitalized patients. Am Heart J 2004; 147 331-8.
6. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43:61-7.
7. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal functions in congestive heart failure. J Card Fail 2002; 8:136-41.
8. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Eng J Med 2000; 343 246-53.
9. Publication Committee for the VMAC investigators. Inravenous nesiritide vs nitroglycerine for the treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002; 287 1531-40.
10. Butler J, Emerman C, Peacock WF, Mathur VS, Young JB, VMAC study investigators. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant 2004; 19:391-9.
11. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal functions with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111:1487-91.
12. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson KD. Short term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005; 293 1900-5.
13. Hauptman P, Schnitzler MA, Swindle J, Burroughs TE. Use of nesiritide before and after publications suggesting drug related risks in patients with acute decompensated heart failure. JAMA 2006; 296 1877-84.
14. Cheng JW, Merl MY, Nguyen HM. Effect of nesiritide on renal functions: A retrospective review. Cur Med Res Opin 2005; 21:1857-61.
15. Iglesias J, Hom D, Antoniotti M, Ayoub S, Levine JS. Predictors of worsening renal functions in adult patients with congestive heart failure receiving recombinant human B-type brain natriuretic peptide (nesiritide). Nephrol Dial Transplant 2006; 21:3458-65.
16. Yancy CW, Saltzberg MT, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K, Oren RM, Walker K, Horton DP, Silver MA. Safety and physibility of using serial infusion of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004; 94:595-601.
17. Chow SL, Peng JT, Okamoto MP, Heywood JT. Effect of nesiritide duration on renal function in acutely decompensated heart failure patients. Ann Pharmacother 2007; 41:556-61.
18. Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R, et al. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: Study rationale and design. Am Heart J 2007; 153:478-84.
19. Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery E, Fisher ML, Rao K, Gottlieb SS. Nesiritide doesn't improve renal functions in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110:1620-5.
20. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J 2006; 152:1084-90.